Logo image of ARMP

ARMATA PHARMACEUTICALS INC (ARMP) Stock Fundamental Analysis

NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD

1.89  -0.01 (-0.53%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ARMP. ARMP was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of ARMP have multiple concerns. ARMP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARMP had negative earnings in the past year.
ARMP had a negative operating cash flow in the past year.
ARMP had negative earnings in each of the past 5 years.
ARMP had a negative operating cash flow in each of the past 5 years.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ARMP's Return On Assets of -0.49% is amongst the best of the industry. ARMP outperforms 89.55% of its industry peers.
Industry RankSector Rank
ROA -0.49%
ROE N/A
ROIC N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARMP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARMP has more shares outstanding
ARMP has a worse debt/assets ratio than last year.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ARMP has an Altman-Z score of -7.88. This is a bad value and indicates that ARMP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.88, ARMP is not doing good in the industry: 70.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.88
ROIC/WACCN/A
WACC6.96%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.12 indicates that ARMP may have some problems paying its short term obligations.
ARMP has a worse Current ratio (0.12) than 97.12% of its industry peers.
ARMP has a Quick Ratio of 0.12. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ARMP (0.12) is worse than 96.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

ARMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.56%, which is quite impressive.
The Revenue has decreased by -0.11% in the past year.
The Revenue has been growing slightly by 5.00% on average over the past years.
EPS 1Y (TTM)98.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.01%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-49.17%

3.2 Future

The Earnings Per Share is expected to grow by 16.20% on average over the next years. This is quite good.
Based on estimates for the next years, ARMP will show a very strong growth in Revenue. The Revenue will grow by 78.86% on average per year.
EPS Next Y-280.54%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2027 2028 10M 20M 30M 40M 50M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 200 -200 400 600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.83%
EPS Next 3Y4.37%

More info and screens

0

5. Dividend

5.1 Amount

ARMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (7/1/2025, 9:28:00 PM)

1.89

-0.01 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners2.05%
Inst Owner Change-46.69%
Ins Owners0.11%
Ins Owner Change0%
Market Cap68.40M
Analysts82.86
Price Target9.18 (385.71%)
Short Float %1.22%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84%
Min EPS beat(2)48.4%
Max EPS beat(2)119.61%
EPS beat(4)4
Avg EPS beat(4)92.8%
Min EPS beat(4)47.48%
Max EPS beat(4)155.7%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)6
Avg EPS beat(12)9.59%
EPS beat(16)9
Avg EPS beat(16)7.45%
Revenue beat(2)0
Avg Revenue beat(2)-43.75%
Min Revenue beat(2)-65.13%
Max Revenue beat(2)-22.38%
Revenue beat(4)1
Avg Revenue beat(4)9.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)223.86%
Revenue beat(8)3
Avg Revenue beat(8)9.44%
Revenue beat(12)4
Avg Revenue beat(12)2.25%
Revenue beat(16)7
Avg Revenue beat(16)14.97%
PT rev (1m)28.57%
PT rev (3m)28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-95%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0.13
BVpS-1.49
TBVpS-1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.77%
Cap/Sales 36.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z -7.88
F-Score4
WACC6.96%
ROIC/WACCN/A
Cap/Depr(3y)409.33%
Cap/Depr(5y)282.59%
Cap/Sales(3y)85.41%
Cap/Sales(5y)77.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.01%
EPS Next Y-280.54%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue 1Y (TTM)-0.11%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%-49.17%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%
EBIT growth 1Y-1.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.75%
OCF growth 3YN/A
OCF growth 5YN/A